MedPage Today (11/24, Rudd) reports, “Human papillomavirus (HPV) vaccination slashed cervical cancer incidence, reduced the risk of precancerous lesions and anogenital warts, and did so without increasing serious side effects, according to two large meta-analyses.” In a “meta-analysis of 225 observational studies with more than 132 million people, females ages 16 years or younger who received HPV vaccines were 80% less likely than their unvaccinated counterparts to develop cervical cancer (RR 0.20, 95% CI 0.09-0.44).” The other meta-analysis, which “included 60 randomized controlled trials (RCTs) with 157,414 participants,” found that “in females ages 15-25 years, vaccination was linked to a 30% reduction in CIN2+ after 6 years regardless of HPV type (RR 0.70, 95% CI 0.56-0.88),” while “CIN2+ risk from vaccine-matched HPV types fell 60% after 6 years (RR 0.40, 95% CI 0.30-0.54).” The findings were published in the Cochrane Database of Systematic Reviews.
Related Links:
— MedPage Today (requires login and subscription)